These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 10073373)

  • 21. Quality of life and its association with insight, adverse effects of medication and use of atypical antipsychotics in patients with bipolar disorder and schizophrenia in remission.
    Yen CF; Cheng CP; Huang CF; Yen JY; Ko CH; Chen CS
    Bipolar Disord; 2008 Jul; 10(5):617-24. PubMed ID: 18657246
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia.
    Loosbrock DL; Zhao Z; Johnstone BM; Morris LS
    J Ment Health Policy Econ; 2003 Jun; 6(2):67-75. PubMed ID: 14578539
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The relationship between patient satisfaction and treatment outcomes in schizophrenia.
    Chue P
    J Psychopharmacol; 2006 Nov; 20(6 Suppl):38-56. PubMed ID: 17046986
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preferences for health outcomes and cost-utility analysis.
    Torrance GW
    Am J Manag Care; 1997 May; 3 Suppl():S8-20. PubMed ID: 10180342
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patient preferences and cost-utility analysis.
    Elnitsky CA; Stone P
    Appl Nurs Res; 2005 May; 18(2):74-6. PubMed ID: 15991103
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of schizophrenia: let's talk dollars and sense.
    Buckley PF
    Am J Manag Care; 1998 Mar; 4(3):369-83. PubMed ID: 10178499
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Should clozapine continue to be restricted to third-line status for schizophrenia?: a decision-analytic model.
    Wang PS; Ganz DA; Benner JS; Glynn RJ; Avorn J
    J Ment Health Policy Econ; 2004 Jun; 7(2):77-85. PubMed ID: 15208468
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Quality of life instruments and health state preferences to assess effects of medical interventions for mentally and medically ill patients].
    Roick C; Thierfelder K; Heider D; Klemm T; Paschke R; Angermeyer MC
    Psychiatr Prax; 2004 Apr; 31(3):128-37. PubMed ID: 15042476
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The impact of antipsychotic medication on the incidence and the costs of inpatient treatment in people with schizophrenia: results from a prospective observational study].
    Kilian R; Angermeyer MC
    Psychiatr Prax; 2004 Apr; 31(3):138-46. PubMed ID: 15042477
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relative association of treatment-emergent adverse events with quality of life of patients with schizophrenia: post hoc analysis from a 3-year observational study.
    Adrianzén C; Arango-Dávila C; Araujo DM; Ruíz I; Walton RJ; Dossenbach M; Karagianis J
    Hum Psychopharmacol; 2010 Aug; 25(6):439-47. PubMed ID: 20737517
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quality-of-life assessment in schizophrenia: the unfulfilled promise.
    Awad AG
    Expert Rev Pharmacoecon Outcomes Res; 2011 Oct; 11(5):491-3. PubMed ID: 21958091
    [No Abstract]   [Full Text] [Related]  

  • 32. The promises and pitfalls of pharmacoeconomics in schizophrenia.
    Patel A
    Eur Psychiatry; 2003 Dec; 18 Suppl 2():62s-67s. PubMed ID: 23570198
    [No Abstract]   [Full Text] [Related]  

  • 33. [Müller S, Kissling W (Pro), Stiegler (contra). Financial motivation for promoting compliance. Psychiatric Praxis 2009; 36: 258-260. A more focused contra is necessary].
    Böhme F
    Psychiatr Prax; 2009 Nov; 36(8):401. PubMed ID: 19938237
    [No Abstract]   [Full Text] [Related]  

  • 34. [Time for an efficiency assessment system for patients with schizophrenia].
    Nordén T; Arnlind M; Blecher R; Malm U; Nilsson C; Olausson G; Wanén M
    Lakartidningen; 1991 Jul; 88(30-31):2511-3. PubMed ID: 1907702
    [No Abstract]   [Full Text] [Related]  

  • 35. Self-reported life satisfaction.
    Rohland BM; Langbehn DR
    Am J Psychiatry; 1997 Oct; 154(10):1478-9. PubMed ID: 9326847
    [No Abstract]   [Full Text] [Related]  

  • 36. Contingency valuation and preferences of health states associated with side effects of antipsychotic medications in schizophrenia.
    Sevy S; Nathanson K; Schechter C; Fulop G
    Schizophr Bull; 2001; 27(4):643-51. PubMed ID: 11824490
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Compliance, persistence, costs and quality of life in young patients treated with antipsychotic drugs: results from the COMETA study.
    Cortesi PA; Mencacci C; Luigi F; Pirfo E; Berto P; Sturkenboom MC; Lopes FL; Giustra MG; Mantovani LG; Scalone L
    BMC Psychiatry; 2013 Mar; 13():98. PubMed ID: 23522406
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quality of life and treatment costs in schizophrenic outpatients, treated with depot neuroleptics.
    Dernovsek MZ; Prevolnik Rupel V; Rebolj M; Tavcar R
    Eur Psychiatry; 2001 Dec; 16(8):474-82. PubMed ID: 11777738
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacoeconomics: state of the art in 1997.
    Schulman KA; Linas BP
    Annu Rev Public Health; 1997; 18():529-48. PubMed ID: 9143730
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Policy toward second-generation antipsychotic drugs: a cautionary note.
    Frank RG
    Psychiatr Serv; 2008 May; 59(5):521-2. PubMed ID: 18451008
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.